Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Anjali S. Advani(Cleveland Clinic), Matthias Stelljes(University Hospital Münster), Erik Vandendries(Pfizer (United States)), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Nicola Gökbuget(Goethe University Frankfurt), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Michaela Liedtke(Cancer Prevention Institute of California), Tao Wang(Pfizer (United States)), Jane Liang White(Pfizer (United States)), Wendy Stock(University of Chicago), Barbara Sleight(Pfizer (United States)), Susan O’Brien(University of California, Irvine)
Cited by 327
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k